MyDosageBeta
← Pick a different goal
MyDosage · Personal evidence dossier

Muscle & body comp

GH secretagogue and incretin combinations for lean tissue.

DSR-MUSC-20260820
Issued August 20, 2026
Editorial · independent
01Top candidate
Sermorelin
GHRH analogue · t½ ~10–20 min

Synthetic GHRH(1-29) historically marketed as Geref. Common in US anti-aging compounding.

Evidence Intelligence Score™
6.5/ 10Moderate
Strongest

Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.

Weakest

Effect sizes outside trial populations and durations beyond the studied window remain less characterized.

Unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Outlook

Outlook: maturing. Expect the consensus to harden as multi-site replications publish.

02Ranked candidates
  1. 01
    Sermorelin
    GHRH analogue
    6.5
    A
  2. 02
    Tesamorelin
    GHRH analogue (stabilised)
    6.5
    A
  3. 03
    MK-677
    Oral ghrelin mimetic
    6.4
    A
  4. 04
    CJC-1295 (with DAC)
    GHRH analogue (long-acting)
    3.9
    C
  5. 05
    Ipamorelin
    Growth hormone secretagogue
    3.9
    C
03Safety register
  • Sermorelin
    Active malignancy · Hypothyroidism (uncontrolled)
  • Tesamorelin
    Active malignancy · Pregnancy · Hypopituitarism
  • MK-677
    CHF · Diabetes (caution) · Active malignancy
  • CJC-1295 (with DAC)
    Active malignancy · Pregnancy
  • Ipamorelin
    Active malignancy · Pregnancy

Suggestive, never prescriptive. This dossier summarizes indexed published evidence as of issue date. It is not medical advice. Discuss with a clinician.

Issued by
MyDosage Editorial
Independent · non-commercial

Dossiers regenerate against the latest evidence on every visit · methodology